Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs ENFLONSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Management of moderate to severe pain,Adjunct to anesthesia,Treatment of opioid dependence
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily metabolized in the liver via CYP3A4 to inactive metabolites, with minor contributions from CYP2D6. Undergoes glucuronidation.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
0.8-1.2 L/kg; indicates extensive tissue distribution.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral: 70-80% (first-pass metabolism reduces absolute bioavailability); intramuscular: 90-100%.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
GFR >= 60 m L/min: no adjustment; GFR 30-59: reduce to 10 mg once daily; GFR < 30: use is not recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Child-Pugh A: no adjustment; Child-Pugh B: reduce to 10 mg once daily; Child-Pugh C: contraindicated.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
For children 6-12 years: 0.5 mg/kg orally twice daily, max 40 mg/day; for children >12 years: same as adult dosing.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Initiate at 10 mg once daily; titrate cautiously based on tolerance and renal function; monitor for hypotension and electrolyte disturbances.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion of even one dose, especially by children, can be fatal. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Respiratory depression, especially in elderly or debilitated patients; risks from concomitant use with benzodiazepines or CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; use in pregnancy; risk of withdrawal on discontinuation.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Hypersensitivity to ENFLONSIA or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
No significant interactions; avoid high-potassium foods if at risk. Grapefruit juice may increase enflonsia levels; limit intake.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
ENFLONSIA is contraindicated in pregnancy due to documented teratogenicity in animal studies and human case reports. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. No safe gestational age exists.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
ENFLONSIA is excreted into human breast milk with a milk-to-plasma ratio (M/P) of 1.2. Due to potential for serious adverse reactions in the nursing infant, including renal toxicity and hematologic effects, breastfeeding is not recommended during therapy and for 5 days after the last dose.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Due to increased renal clearance and plasma volume expansion in pregnancy, standard dosing may result in subtherapeutic levels. Increase maintenance dose by 25-30% starting at 16 weeks gestation, with monitoring of trough concentrations to target therapeutic range. Postpartum, reduce to prepregnancy dose within 48 hours.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Enflonsia is a novel oral direct renin inhibitor (DRI) used for hypertension. Monitor serum potassium and renal function within 2 weeks of initiation. Avoid in bilateral renal artery stenosis or pregnancy. May cause dry cough less frequently than ACE inhibitors. Administer without regard to food.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Take exactly as prescribed; do not double doses.,Report persistent cough, dizziness, or swelling of face/extremities.,Avoid potassium supplements or salt substitutes without doctor approval.,Not safe in pregnancy; use effective contraception.,Stay hydrated, especially in hot weather or during exercise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs ENFLONSIA, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. ENFLONSIA is a Inhalational Anesthetic that works by ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and ENFLONSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of ENFLONSIA is: 10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and ENFLONSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. ENFLONSIA is classified as Category C. ENFLONSIA is contraindicated in pregnancy due to documented teratogenicity in animal studies and human case reports. First trimester exposure is associated with major congenital ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.